Literature DB >> 10146968

Pharmacoeconomic evaluation to assist prescription drug pricing: a US perspective on an international issue.

R J Bonk, W F McGhan.   

Abstract

Mesh：

Year:  1993        PMID： 10146968     DOI： 10.2165/00019053-199304020-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  15 in total

Review 1.  A prescription for high drug prices.

Authors:  D Pryor
Journal:  Health Aff (Millwood)       Date:  1990       Impact factor: 6.301

Review 2.  New drug legislation: a response from the pharmaceutical industry.

Authors:  P E Freiman
Journal:  Health Aff (Millwood)       Date:  1990       Impact factor: 6.301

Review 3.  Managed care and a changing pharmaceutical industry.

Authors:  M R Pollard
Journal:  Health Aff (Millwood)       Date:  1990       Impact factor: 6.301

4.  Are prescription drug prices high?

Authors:  P R Vagelos
Journal:  Science       Date:  1991-05-24       Impact factor: 47.728

Review 5.  Trends in retail prescription expenditures.

Authors:  S W Schondelmeyer; J Thomas
Journal:  Health Aff (Millwood)       Date:  1990       Impact factor: 6.301

Review 6.  The elderly and drug policy: coming of age.

Authors:  J Avorn
Journal:  Health Aff (Millwood)       Date:  1990       Impact factor: 6.301

7.  Guidelines for pharmacoeconomic studies.

Authors:  W F McGhan; N J Lewis
Journal:  Clin Ther       Date:  1992 May-Jun       Impact factor: 3.393

8.  Pharmacoeconomic research and clinical trials: concepts and issues.

Authors:  J L Bootman; L N Larson; W F McGhan; R J Townsend
Journal:  DICP       Date:  1989-09

9.  National health expenditures projections through 2030.

Authors:  S T Burner; D R Waldo; D R McKusick
Journal:  Health Care Financ Rev       Date:  1992

10.  National health expenditures, 1989.

Authors:  H C Lazenby; S W Letsch
Journal:  Health Care Financ Rev       Date:  1990
View more
  2 in total

1.  Drug expenditures in a balanced strategy for healthcare policy.

Authors:  R J Bonk; M J Myers; W F McGhan
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

2.  Economics of the antithymocyte globulins Thymoglobulin and Atgam in the treatment of acute renal transplant rejection.

Authors:  M A Schnitzler; R S Woodward; J A Lowell; L Amir; T J Schroeder; G G Singer; D C Brennan
Journal:  Pharmacoeconomics       Date:  2000-03       Impact factor: 4.981
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.